指南与共识类风湿关节炎脊柱关节炎

换或不换:丹麦全国强制性从依那西普原研药换用生物类似药的指南结果——DANBIO登记中2061例炎性关节炎患者的一年治疗结局

To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
指南 / 共识 · Ann Rheum Dis · 2018-11-05

基于DANBIO登记的前瞻性队列研究,2016年丹麦发布全国指南强制炎性关节炎患者从依那西普原研药(ETA)换用生物类似药(SB4)。2061例ETA治疗患者中1621例(79%)换用SB4,换药前后3个月疾病活动度无变化。调整后1年治疗保留率:换药组83%(79%–87%),未换药组77%(72%–82%),历史队列90%(88%–92%)。未缓解患者保留率更低。

要点

  • 79%的ETA治疗患者按指南换用SB4,换药前后3个月疾病活动度无变化。
  • 调整后1年保留率换药组83%、未换药组77%、历史队列90%。
  • 未缓解患者保留率更低:换药组粗HR 1.7(1.3–2.2),未换药组2.4(1.7–3.6)。

核心结论

  • 79%的ETA治疗患者换用SB4,调整后1年保留率换药组低于历史ETA队列但高于未换药组。
  • 停药更常见于未缓解患者,提示常规诊疗中换药结局受患者相关因素和非特异性药物效应影响。

研究设计与样本

  • 基于DANBIO登记的前瞻性观察性队列研究。
  • 纳入2061例ETA治疗的类风湿关节炎、银屑病关节炎或中轴型脊柱关节炎患者,其中1621例(79%)换用SB4。
  • 采用Kaplan-Meier法和Cox回归(粗分析、调整分析)比较治疗保留率,并描述换回ETA患者的特征。

主要发现

  • 换药前后3个月疾病活动度无变化。
  • 调整后1年保留率:未换药组77%(95%CI 72%–82%),换药组83%(79%–87%),历史队列90%(88%–92%)。
  • 未缓解患者保留率更低:换药组粗HR 1.7(1.3–2.2),未换药组2.4(1.7–3.6)。
  • 随访期间120例(换药组的7%)换回ETA,其临床特征与换药组相似,SB4停药原因主要为主观因素。

关键数值与推荐

  • 2016年丹麦发布全国指南,强制类风湿关节炎、银屑病关节炎和中轴型脊柱关节炎患者从50 mg依那西普原研药(ETA)换用生物类似药(SB4)。
  • 未换药患者常使用25 mg ETA(ETA 25 mg笔/注射器和粉末溶液仍可用)。

临床怎么用

  • 常规诊疗中从原研依那西普换用生物类似药SB4总体可行,换药后短期疾病活动度稳定。
  • 未缓解患者换药后停药风险更高,换药决策需结合疾病活动状态和患者因素个体化评估。

局限性

  • 观察性研究,非随机分组,换药组与未换药组间可能存在混杂因素。
  • 未换药患者常使用25 mg ETA,剂量差异可能影响组间比较。
  • 历史队列来自不同时期,治疗保留率的比较可能受时间趋势影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Real-world evidence on effectiveness of switching to biosimila r etanercept is scarce. In Denmark, a nationwide guideline of mandatory switch from 50 mg originator (ETA) to biosimilar (SB4) etanercept was issued for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) in 2016. Clinical characteristics and treatment outcomes were studied in ETA-treated patients, who switched to SB4 (switchers) or maintained ETA (non-switchers). Retention rates were compared with that of a historic cohort of ETA-treated patients. Switchers who resumed ETA treatment (back-switchers) were characterised. METHODS: Observational cohort study based on the DANBIO registry. Treatment retention was explored by Kaplan-Meier plots and Cox regression (crude, adjusted). RESULTS: 1621 (79%) of 2061 ETA-treated patients switched to SB4. Disease activity was unchanged 3 months' preswitch/postswitch. Non-switchers often received 25 mg ETA (ETA 25 mg pens/syringes and powder solution were still available). One-year adjusted retention rates were: non-switchers: 77% (95% CI: 72% to 82%)/switchers: 83% (79% to 87%)/historic cohort: 90% (88% to 92%). Patients not in remission had lower retention rates than patients in remission, both in switchers (crude HR 1.7 (1.3 to 2.2)) and non-switchers (2.4 (1.7 to 3.6)). During follow-up, 120 patients (7% of switchers) back-switched to ETA. Back-switchers' clinical characteristics were similar to switchers, and reasons for SB4 withdrawal were mainly subjective. CONCLUSION: Seventy-nine per cent of patients switched from ETA to SB4. After 1 year, adjusted treatment retention rates were lower in switchers versus the historic ETA cohort, but higher than in non-switchers. Withdrawal was more common in patients not in remission. The results suggest that switch outcomes in routine care are affected by patient-related factors and non-specific drug effects.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Glintborg B, Loft AG, Omerovic E, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis. 2018. PMID: 30396903. doi:10.1136/annrheumdis-2018-213474

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。